Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Retreatment With Brentuximab Vedotin in Relapsed or Refractory Classic Hodgkin Lymphoma
2019-003983-28Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- May 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma (PTCL), sponsored by Seagen Inc. Primary endpoint: Objective response rate by BICR. Started May 2021; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)anaplastic large cell lymphoma (ALCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on 2019-003983-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003983-28.